As China's leading cutting-edge technology company in the R&D and production of human organ chips, Daxiang Technology has been selected into the third phase of the Merck China Accelerator project. In the future, it will discuss potential cooperation opportunities with Merck's internal experts.
The shortlisted companies of Merck Accelerator will engage in innovative cooperation with Merck in the future, receive guidance from Merck's internal experts and external industry leaders, receive financial support and additional investment opportunities, and have the opportunity to further obtain global network resource support
Beijing Daxiang Technology Co., Ltd., as China's leading cutting-edge technology company in research and development and production of human organ chips, is committed to promoting and leading the wide application of organ chips in new drug research and development, life science, medical research, personalized medicine and other fields, focusing on the development of tumor, liver, barrier related pathophysiological models and innovative organ like chips, and expects to provide more accurate, efficient and economical drug research and development and precision Medication solutions to promote the development of human health. Taking the human primary hepatotoxicity model developed by the company as an example, the clinical prediction rate of hepatotoxicity can reach
1003
